United States: FDA Finalizes Benefit-Risk Determination Methodology For Certain Medical Devices

Last Updated: April 19 2012
Article by James Cohen, Glenn Engelmann and Michael W. Ryan

In an attempt to improve the predictability, consistency and transparency of the medical device review process, the U.S. Food and Drug Administration (FDA) recently released final guidance describing the principal factors the agency will consider when making benefit-risk determinations during the premarket approval and de novo classification processes, respectively. In this newsletter, we provide a brief summary of the final guidance document and describe some of its implications.

On March 27, 2012, the U.S. Food and Drug Administration (FDA) released a final guidance document describing the principal factors the agency will consider when making benefit-risk determinations for medical devices subject to the premarket review and de novo classification processes, respectively. The final guidance, entitled "Factors to Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications," describes the types of medical devices to which the guidance applies, identifies the types of scientific evidence FDA will consider when making benefit-risk determinations, enumerates a series of factors FDA will consider in making such determinations and provides a series of examples illustrating the manner in which FDA will use such factors to make benefit-risk determinations.

Scope of the Final Guidance

The final guidance applies to both diagnostic and therapeutic devices that are subject to premarket approval (PMA) or de novo classification petitions. This represents a shift from the scope of the draft guidance, which addressed the factors for PMA devices and, "in limited cases, [for] devices subject to premarket notification (510(k)) requirements," but did not address the factors for devices that are the subject of a de novo classification petition.

FDA states the contents of the final guidance should be considered during the design, non-clinical testing, pre-Investigational Device Exemption (IDE) and IDE phases, as well as in assembling and assessing PMAs or de novo petitions. Under the Federal Food, Drug, and Cosmetic Act, sponsors of low- to moderate-risk devices that have been determined by FDA to be not substantially equivalent to a predicate device may submit a petition to the FDA requesting de novo classification and marketing authorization for the device.

Types of Scientific Evidence that Will Be Considered During Risk-Benefit Analysis

Unsurprisingly, FDA states it puts a "great deal of emphasis" on results obtained using clinical testing methods (e.g., randomized controlled trials, well-controlled investigations, testing on clinically-derived human specimens). However, FDA acknowledges that, in certain situations, non-clinical data (e.g., data generated by performance testing for product safety, reliability and/or characterization, computer simulations) may play an important role in demonstrating the safety and effectiveness of a medical device, as medical devices often have attributes that cannot be tested using clinical methods alone. As such, both clinical and non-clinical data may be useful in demonstrating the safety and/or effectiveness of a device.

Factors FDA Considers in Making Benefit-Risk Determinations

In the final guidance, FDA groups into three categories the factors the agency will use when making benefit-risk determinations: the factors to be used in assessing the benefits of devices, the factors to be used in assessing the risks of devices, and additional factors to be used in the assessment of the probable benefits and risks of devices.

In assessing the benefits associated with the use of a device, FDA will consider:

  • Types of benefits—What primary endpoints, secondary endpoints or surrogate endpoints were considered? What value do patients place on the benefit?
  • Magnitude of benefits—What was the magnitude of treatment effect for each endpoint? What scale is used to measure the benefit? How did the benefit rank on that scale?
  • Probability of a patient experiencing one or more benefits—Was the study able to predict which patients will experience a benefit? What is the probability that a patient for whom the device is intended will experience a benefit? How did benefits evaluated vary across subpopulations?
  • Duration of effects—Could the duration of each treatment effect (including primary and secondary endpoints) be determined (if relevant)? Is the duration of benefit achieved of value to patients?

With respect to the assessment of risks, FDA will take the following factors into account:

  • Severity, type(s), number and rate(s) of harmful events associated with the use of the device—What are the device-related serious adverse events, device-related non-serious adverse events and other procedure-related complications that a patient may be subject to?
  • Probability of a harmful event—What percentage of the intended patient population would expect to experience a harmful event? What is the incidence of each harmful event? Is there uncertainty in that estimate? How does the incidence of harmful events vary by subpopulation? Are patients willing to accept the probable risk of the harmful event given the probable benefits of the device?
  • Duration of harmful events—How long does the harmful event last? Is it reversible? What type of intervention is required to address the harmful event?
  • Risk of false-positive or false-negative results from diagnostics—What are the consequences of a false positive? What are the consequences of a false negative? Does the device provide the only means of diagnosing the problem, or is it part of an overall diagnostic plan?
  • Aggregate effect of harmful events—Do multiple harmful events occur at once?

Finally, FDA identifies a category of "additional factors" to be used in the assessment of benefits and risks:

  • Uncertainty—How robust were the data? How was the trial designed, conducted and analyzed? Are the results repeatable? Is the study the first of a kind, or have other studies achieved similar results? Can the results of the study be applied to the population generally, or are they intended for discrete, specific groups?
  • Characterization of the disease—How does the disease affect the patients that have it? Is the condition treatable? How does the condition progress?
  • Patient tolerance for risk and perspective on benefit—Did the sponsor present data regarding how patients tolerate the risks posed by the device? Are the risks identifiable and definable? Is the disease so severe that patients will tolerate a higher amount of risk for a smaller benefit? Is the disease chronic? How long do patients with the disease live? If the disease is chronic, is illness easily managed with less invasive or difficult therapies? Are patients willing to take the risk of this treatment to achieve the benefit? How well are patients able to understand the risks and benefits?
  • Availability of alternative treatments or diagnostics—What other therapies are available for this condition? How effective are the alternative treatments? How well-tolerated are the alternative treatments? What risks are presented by the alternative treatments?
  • Risk mitigation—Are there ways to mitigate risks (e.g., product labeling, establishing educational programs, providing add-on therapy, etc.)? What type of mitigation strategy is proposed?
  • Postmarket data—Are the probabilities of effectiveness and the rates of harmful events for similar devices similar to what is expected for the device under review? Is there reason to believe that long-term device performance, effectiveness of provider training programs, safety and/or efficacy of the device in subgroups or rare adverse events should be evaluated in the postmarket setting? Is there a reason to expect a significant difference between "real world" performance of the device and the performance found in premarket trials? Are there any data that would be provided to support approval that could be deferred to the postmarket setting?
  • Novel technology addressing unmet medical need—How well is the medical need this device addresses being met by currently available therapies? How desirable is this device to patients?

Appendix B of the final guidance includes a worksheet that clearly summarizes the above-listed factors that reviewers will use in making benefit-risk determinations as part of the PMA or de novo classification process. Appendix C provides useful examples of how reviewers might utilize the worksheet in the review of products. As such, these appendices provide a clear roadmap for device manufacturers to follow and may facilitate smoother approval of innovative devices.

Implications

In issuing this helpful final guidance, FDA indicates a commendable willingness to undertake a more flexible and transparent approach to benefit-risk determinations, at least as to devices subject to PMA and de novo review. The multi-factor approach to benefit-risk assessment described in the final guidance, if appropriately implemented, will enable FDA to conduct an individualized assessment of each medical device subject to PMA or de novo classification. Moreover, by explicitly stating the criteria FDA will use to assess the above-referenced submissions, device manufacturers should be better able to anticipate the types of data they will need to submit to support a PMA or de novo petition.

In particular, the final guidance is notable in that it indicates FDA is willing to consider a patient's informed request to utilize a device as evidence that such device should be made publicly available—even in situations where the agency might otherwise consider such device to be too risky. In recent years, FDA has been the subject of some criticism for declining to approve products intended to treat serious or chronic conditions when it deems them to raise issues relative to their risk. Although it remains to be seen whether FDA will consider patient risk tolerance data to be persuasive, the final guidance represents, at minimum, a nominal step toward embracing broader benefit-risk factors and potentially increasing patient access to innovative medical devices.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
James Cohen
 
In association with
Related Video
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert
Email Address
Company Name
Password
Confirm Password
Mondaq Topics -- Select your Interests
Accounting and Audit
Anti-trust/Competition Law
Consumer Protection
Corporate/Commercial Law
Criminal Law
Employment and HR
Energy and Natural Resources
Environment
Family and Matrimonial
Finance and Banking
Food, Drugs, Healthcare, Life Sciences
Government, Public Sector
Immigration
Insolvency/Bankruptcy, Re-structuring
Insurance
Intellectual Property
International Law
Law Practice Management
Litigation, Mediation & Arbitration
Media, Telecoms, IT, Entertainment
Privacy
Real Estate and Construction
Strategy
Tax
Transport
Wealth Management
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.